Payment overview · 2025
General Payments
$16,461.31
117 reported records · 16 companies
Healthcare provider profile · identity verified
Safwan Hamwi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LA FOLLETTE, TN · NPI 1396940656
Verified facts
What the public records show
CMS Open Payments records show Safwan Hamwi, M.D. received $16,461.31 in general payments during 2025 across 117 reported records.
CeQur Corporation accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Jardiance, Kerendia, Korlym, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Korlym by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CeQur Corporation | Unresolved — no canonical attribution shown | $7,178.07 | 43.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6,319.03 | 38.4% | 36 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,205.01 | 7.3% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $562.94 | 3.4% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $326.96 | 2.0% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$238.55 | 1.4% | 10 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $206.92 | 1.3% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $124.59 | 0.8% | 5 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.67 | 0.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.13 | 0.3% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $43.57 | 0.3% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $35.29 | 0.2% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $34.61 | 0.2% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $29.62 | 0.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.66 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.69 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,667.50 | 2 |
| Honoraria | $4,500.00 | 3 |
| Food and Beverage | $3,019.21 | 104 |
| Travel and Lodging | $1,232.10 | 7 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $7,178.07 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $5,961.65 | 24 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,205.01 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $562.94 | 24 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $357.38 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $326.96 | 14 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $238.55 | 10 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $206.92 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $124.59 | 5 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $43.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 183 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 75 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
183 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 178 |
| Mounjaro | Tirzepatide | 464 | 60 |
| Humalog | Insulin Lispro | 263 | 49 |
| Ozempic | Semaglutide | 217 | 40 |
| Jardiance | Empagliflozin | 183 | 28 |
| Insulin Lispro | Insulin Lispro | 152 | 34 |
| Tradjenta | Linagliptin | 134 | 21 |
| Novolog | Insulin Aspart | 129 | 29 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 120 | 21 |
| Metformin Hcl | Metformin Hcl | 100 | 19 |
| Glimepiride | Glimepiride | 96 | 20 |
| Glyxambi | Empagliflozin/Linagliptin | 82 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 20 |
| Methimazole | Methimazole | 77 | 21 |
| Kerendia | Finerenone | 75 | 12 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 74 | 18 |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 61 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 60 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 12 |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 50 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Prednisone | Prednisone | 44 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 41 | 22 |
| Hydrocortisone | Hydrocortisone | 39 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 34 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 31 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Gabapentin | Gabapentin | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cycloset | Bromocriptine Mesylate | 16 | suppressed |
| Afrezza | Insulin Regular, Human | 15 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Omnipod Classic Pods (Gen 3) | Insulin Pump Cart,cont Inf,rf | 14 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alogliptin-Pioglitazone | Alogliptin Benz/Pioglitazone | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Korlym | Mifepristone | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,461.31 · 117 records | CeQur Corporation | AFREZZA, CeQur Simplicity, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, ID NOW INSTRUMENT, JARDIANCE, Kerendia, Korlym, MINIMED 780G, Ozempic, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REPATHA, TWIIST, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error